Dear valued clients and partners,
We have been experiencing a major coronavirus outbreak since this Chinese New Year holiday. With everyone’s efforts,
WuXi Oncology & Immunology Unit (OIU) officially returned to work on February 12th
. We thank you all for your continuous support and trust in WuXi OIU during this special period. Let us collaborate together, to do the right thing and do it right, and win back a fruitful 2020!
In the current issue of the OncoWuXi Newsletter, we would like to share with you our updates on
genetically engineered Ba/F3 cell lines and corresponding
. Other interesting topics covered in this issue include the updates on our integrated target identification and validation platform and FGFR targeted
OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.